DMG-PEG 2000 is a novel long-circulating lipid material that can be used for preparing liposomes for siRNA transfection, enhancing transfection efficiency. It can also be employed in preparing lipid nanoparticles (LNPs) for the oral delivery of plasmid DNA in vivo, improving the mucosal permeability and delivery efficiency of LNPs.
NMPA CDE registration no.: F20210000451
USFDA DMF no.: 036553
Product Name | 1,2-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol-2000(DMG-PEG2000) |
Chemical Name | 1,2-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol-2000 |
CAS No. | 160743-62-4 |
NMPA CDE registration no. | F20210000451 |
USFDA DMF No. | 036553 |
Quality grade | Injection |
Quality standards | Manufacturer's standard |
Molecular Formula | C32H62O5(C2H4O)n, n≈45 |
Applications and examples | Long circulating liposomes, Moderna COVID-19 vaccine |
Product code | O02005 |
Package sizes | 1g |
Storage condition | -20°C, sealed storage, away from moisture and light *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light) |
Liposome-based nucleic acid drugs utilizing DMG-PEG 2000 demonstrate a quicker dissociation in vivo compared to other long-circulating phospholipids like DSPE-PEG 2000, with a half-life of less than 30 minutes. This facilitates simultaneous enhancement of liver targeting and gene silencing efficiency, achieving better therapeutic efficacy through in vivo long circulation and passive targeting.
DMG-PEG 2000 is a fully synthetic PEGylated short-chain lipid. Its C14 chain is much shorter than the C18 chain of DSPE-mPEG 2000. Its shorter chain allows for rapid dissociation while achieving in vivo escape, countering the failure of "endosomal escape" caused by PEGylation.
If you have any questions, please don't hesitate to contact us. We're always here to help with Pharmaceutical Excipients for your business. We can provide products ranging from grams to tons. AVT is able to produce and even register the product in US FDA according to your special needs.